Health PR
VIVA! Communications welcomes new recruits
Today we have welcomed two new members to VIVA! Communications – PR Consultant Sophie Harrison and Account Executive, Sophie Ridley. Both Sophies will be charged with supporting the servicing of our VIVA! clientele, and further strengthening our agency’s health communications, digital and social expertise. Sophie H specialises in Sports Science and Public Health. She has…
Read MoreGlobal Health Marketing and Communications (GHMC) welcomes Improve Comunicaciones as an exclusive agency partner in Mexico, strengthening network’s capabilities in Latin America
As the exclusive Australian partner of Global Health Marketing and Communications (GHMC) – the largest and most robust network of independent healthcare agencies worldwide – VIVA! Communications extends a warm welcome to our newest member – Improve Comunicaciones. The addition of the Mexican-based, strategic consulting agency to GHMC, strengthens our GHMC network’s offering, and capabilities…
Read MoreNew treatment now PBS listed for Australians living with chronic plaque psoriasis
The October 1, 2023 Pharmaceutical Benefits Scheme (PBS) listing of a new, once-daily, oral treatment for severe chronic plaque psoriasis represents good news for the estimated 19,000 Australian adults living with the common inflammatory skin disease. At VIVA! Communications, we are proud to be supporting the communication of this PBS listing announcement, working in partnership…
Read MoreVIVA! Communications clinches Best PR Campaign – Awareness and Advocacy with Edwards Lifesciences at the 2022 PRIME Awards
VIVA! Communications marked the 18th annual PRIME Awards in style last night (Thursday, November 10, 2022) together with our much-valued clientele, Edwards Lifesciences and Dr Falk Pharma, and Australian representatives from the pharmaceutical industry, at the Sofitel Wentworth Sydney Hotel. Hosted by comedian, musician and former member of ABC TV’s satirical program, The Chaser,…
Read More
First treatment in 10 years PBS listed for Aussies
living with aggressive stomach & oesophageal cancers
Australians living with types of aggressive stomach or oesophageal cancers can now access immunotherapy on the Pharmaceutical Benefits Scheme (PBS), representing the first treatment advance for many of these patients in a decade. OPDIVO® (nivolumab) in combination with chemotherapy, is now reimbursed as an initial treatment for patients with a type of stomach or oesophageal…
Read More